EDAP TMS

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

EDAP TMS reports Q1 revenue growth and FDA breakthrough designation

EDAP TMS reported solid revenue growth in Q1 2024, driven by strong international placements and advancements in Focal One technology. While facing financial challenges, the company is strategically positioned to benefit from the expanding HIFU market and upcoming regulatory milestones. Opportunities lie in market expansion, new study data releases, and continued engagement with regulatory bodies.

EDAP TMS reports strong Q2 earnings, poised for market expansion

EDAP TMS delivered robust performance in Q2 2024, driven by revenue growth and advancements in key medical programs.
While facing challenges in profitability and expenses, the company is strategically positioned to capitalize on market opportunities.
Investments in research, management, and clinical trials signal a proactive approach towards sustainable growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q4 2019 Results - Earnings Call Transcript

LYON, France, March 30, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, announced today financial results for the fourth quarter and full year of 2019 and provided an update on strategic and operational developments. 

EDAP Reports Record Full Year 2019 Results and Provides Operational Update

LYON, France, March 17, 2020 – EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today issued the following letter to shareholders:  

EDAP Issues Letter to Shareholders Providing an Update on COVID-19 and the Potential Impact to Operations

LYON, France, February 18, 2020 – EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company recently showcased its Focal One high intensity focused ultrasound (HIFU) device at the 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, which was held February 9-11 in Washington, DC. This marks the first time that the symposium was held in the U.S. since FDA clearance of Focal One in June 2018.  

EDAP Showcases Focal One at the 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer   

EDAP Announces Sale of Robotic Focal One® HIFU Device to University of Miami

Study confirms feasibility of using Focal One HIFU to treat rectal endometriosis

EDAP Announces Publication of Focal One® Endometriosis Study in the Journal Ultrasound in Obstetrics & Gynecology

LYON, France, November 26, 2019 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in therapeutic ultrasound, announced today that the first Focal One® treatment was performed at Farrer Park Hospital in Singapore.

EDAP Announces First Focal One® HIFU treatments at Farrer Park Hospital in Singapore

EDAP TMS S.A. (EDAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

EDAP TMS S.A. (EDAP) Moves to Buy: Rationale Behind the Upgrade

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q3 2019 Results - Earnings Call Transcript

LYON, France, November 13, 2019 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in therapeutic ultrasound, announced today financial results for the third quarter and nine months of 2019 and provided an update on strategic and operational developments. 

EDAP Reports 2019 Third Quarter and Nine Months Results

The company is in the first inning with its HIFU treatment of prostate cancer, enjoying near triple-rate growth in Q2.

EDAP Is At An Inflection Point

As of late, it has definitely been a great time to be an investor EDAP TMS.

Will EDAP TMS Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in EDAP TMS S.A. (EDAP).

EDAP TMS S.A. (EDAP) Shares March Higher, Can It Continue?

EDAP TMS S.A. (EDAP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

EDAP TMS S.A. (EDAP) Upgraded to Strong Buy: Here's Why

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q2 2019 Results - Earnings Call Transcript

LYON, France, August 28, 2019 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in therapeutic ultrasound, announced today financial results for the second quarter of 2019 and provided an update on strategic and operational developments. 

EDAP Reports 2019 Second Quarter Results

EDAP has been one of the pioneers and proponents of HIFU technology for over 30 years.

EDAP Needs More Focal One Placements To Maintain Investor Support

EDAP TMS S.A.'s (EDAP) CEO Marc Oczachowski on Q1 2019 Results - Earnings Call Transcript

EDAP TMS (EDAP) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

EDAP TMS (EDAP) Looks Good: Stock Adds 7.9% in Session

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q4 2018 Results - Earnings Call Transcript

News for EDAP TMS Stock (EDAP)